Skip to main content

Xenetic Biosciences, Inc.

XBIO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001534525

No open-market purchases or sales by Xenetic Biosciences, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $442.8K in total; no superinvestor holds it.

Holders of 5% or more of XBIO

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Xenetic Biosciences, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of XBIO
HolderLatest formStakeChangeFirst filedLatest filingFiling
Renaissance Technologies LLC13G/A6.00%137.4K shares−1.79 ppfrom 7.79%Feb 12, 20262 filingsMay 14, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

8 Schedule 13D and 13G filings on Xenetic Biosciences, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on XBIO
Filed (ET)FilerFormStakeChangeEvent dateFiling
Sep 18, 20262:35 PM ETMJL Manager LLCand 1 other13G0.00%0 shares−5.50 ppfrom 5.50%Below 5%Sep 16, 2026SEC
May 29, 20264:04 PM ETMJL Manager LLCand 1 other13G5.50%126.7K sharesNewMay 22, 2026SEC
May 14, 20264:47 PM ETRenaissance Technologies LLCand 1 other13G/A6.00%137.4K shares−1.79 ppfrom 7.79%Mar 31, 2026SEC
Feb 12, 20262:15 PM ETRenaissance Technologies LLCand 1 other13G7.79%178.5K sharesNewOct 27, 2025SEC
Mar 18, 2024CLS Therapeutics, LLC13D/AOld format–––SEC
Sep 18, 2023CLS Therapeutics, LLC13D/AOld format–––SEC
Jun 15, 2023CLS Therapeutics, LLC13DOld format–––SEC
Oct 21, 2022CLS Therapeutics, LLC13GOld format–New–SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Xenetic Biosciences, Inc. shares.

No Form 144 notices for Xenetic Biosciences, Inc. are on file.